Treatment results of 165 pediatric patients with non-metastatic nasopharyngeal carcinoma: A Rare Cancer Network study Journal Article
| Authors: | Ozyar, E.; Selek, U.; Laskar, S.; Uzel, O.; Anacak, Y.; Ben-Arush, M.; Polychronopoulou, S.; Akman, F.; Wolden, S. L.; Sarihan, S.; Miller, R. C.; Ozsahin, M.; Abacioǧlu, U.; Martin, M.; Caloglu, M.; Scandolaro, L.; Szutowicz, E.; Atahan, I. L. |
| Article Title: | Treatment results of 165 pediatric patients with non-metastatic nasopharyngeal carcinoma: A Rare Cancer Network study |
| Abstract: | Purpose: This Rare Cancer Network (RCN) study was performed in pediatric nasopharyngeal carcinoma (PNPC) patients to evaluate the optimal dose of radiotherapy and to determine prognostic factors. Patients and Methods: The study included 165 patients with the diagnosis of PNPC treated between 1978 and 2003. The median age was 14 years. There were 3 (1.8%) patients with stage I, 1 (0.6%) with IIA, 10 (6.1%) with IIB, 60 (36.4%) with III, 44 (26.7%) with IVA, and 47 (29%) with IVB disease. While 21 (12.7%) patients were treated with radiotherapy (RT) alone, 144 (87.3%) received chemotherapy and RT. The median follow-up time was 48 months. Results: The actuarial 5-year overall survival (OS) was 77.4% (95% CI: 70.06-84.72), whereas the actuarial 5-year disease-free survival (DFS) rate was 68.8% (95% CI: 61.33-76.31). In multivariate analysis, unfavorable factors were age >14 years for LRC (p = 0.04); male gender for DMFS (p = 0.03); T3/T4 disease for LRFS (p = 0.01); and N3 disease for DFS (p = 0.002) and OS (p = 0.002); EBRT dose of less than 66 Gy for LRFS (p = 0.02) and LRRFS (p = 0.0028); and patients treated with RT alone for LRFS (p = 0.0001), LRRFS (p = 0.007) and DFS (p = 0.02). Conclusion: Our results support the current practice of using combined radiation and chemotherapy for optimal treatment of NPC. However, research should be encouraged in an attempt to reduce the potential for long-term sequelae in pediatric patients given their relatively favorable prognosis and potential for longevity. © 2006 Elsevier Ireland Ltd. All rights reserved. |
| Keywords: | adolescent; cancer chemotherapy; cancer survival; child; controlled study; school child; treatment outcome; disease-free survival; major clinical study; cisplatin; doxorubicin; fluorouracil; adjuvant therapy; cancer radiotherapy; radiation dose; combined modality therapy; methotrexate; cancer staging; follow up; carboplatin; cancer immunotherapy; neoplasm recurrence, local; radiotherapy; cyclophosphamide; vincristine; age factors; retrospective study; cancer therapy; ifosfamide; childhood cancer; pediatric; epidemiologic methods; dactinomycin; bleomycin; cancer relapse; epirubicin; nasopharynx carcinoma; multivariate analysis; sex difference; age distribution; external beam radiotherapy; sex factors; dose fractionation; nasopharynx cancer; nasopharyngeal neoplasms; rare diseases; rare |
| Journal Title: | Radiotherapy and Oncology |
| Volume: | 81 |
| Issue: | 1 |
| ISSN: | 0167-8140 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2006-10-01 |
| Start Page: | 39 |
| End Page: | 46 |
| Language: | English |
| DOI: | 10.1016/j.radonc.2006.08.019 |
| PUBMED: | 16965827 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 12" - "Export Date: 4 June 2012" - "CODEN: RAOND" - "Source: Scopus" |
